Skip to main content

Compare Stocks

Date Range: 

 Replimune GroupAlloVirREGENXBIOAlectorC4 Therapeutics
SymbolNASDAQ:REPLNASDAQ:ALVRNASDAQ:RGNXNASDAQ:ALECNASDAQ:CCCC
Price Information
Current Price$35.05$24.00$36.14$17.00$34.84
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.51.61.31.4
Analysis Score3.53.53.43.53.5
Community Score2.43.52.72.42.8
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.80.0
Earnings & Valuation Score0.00.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$56.00$49.25$62.50$34.40$44.50
% Upside from Price Target59.77% upside105.21% upside72.94% upside102.35% upside27.73% upside
Trade Information
Market Cap$1.63 billion$1.56 billion$1.54 billion$1.36 billion$1.50 billion
Beta2.63N/A1.281.08N/A
Average Volume377,760338,141431,114623,224276,823
Sales & Book Value
Annual RevenueN/AN/A$35.23 million$21.22 millionN/A
Price / SalesN/AN/A43.6163.90N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.01 per shareN/A$12.23 per share$2.83 per shareN/A
Price / BookN/AN/A2.966.01N/A
Profitability
Net Income$-52,630,000.00N/A$-94,730,000.00$-105,390,000.00N/A
EPS($1.54)N/A($3.26)($1.71)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-63.13%-757.78%N/A
Return on Equity (ROE)-30.23%N/A-21.73%-53.86%N/A
Return on Assets (ROA)-24.66%N/A-18.74%-31.44%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.13%N/AN/AN/AN/A
Current Ratio19.47%28.40%6.08%6.61%5.22%
Quick Ratio19.47%28.40%6.08%6.61%5.22%
Ownership Information
Institutional Ownership Percentage55.79%32.07%75.23%61.50%N/A
Insider Ownership Percentage50.90%1.00%14.10%13.90%N/A
Miscellaneous
Employees1225330617199
Shares Outstanding46.49 million65.11 million42.51 million79.77 million43.19 million
Next Earnings Date6/2/2021 (Estimated)9/1/2021 (Estimated)8/5/2021 (Estimated)8/10/2021 (Estimated)8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
C4 Therapeutics (NASDAQ:CCCC) Posts  Earnings Results, Beats Expectations By $0.14 EPSC4 Therapeutics (NASDAQ:CCCC) Posts Earnings Results, Beats Expectations By $0.14 EPS
americanbankingnews.com - May 14 at 2:06 PM
Reviewing C4 Therapeutics (NASDAQ:CCCC) and Vir Biotechnology (NASDAQ:VIR)Reviewing C4 Therapeutics (NASDAQ:CCCC) and Vir Biotechnology (NASDAQ:VIR)
americanbankingnews.com - May 14 at 12:28 PM
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial ResultsC4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
finance.yahoo.com - May 13 at 4:46 PM
C4 Therapeutics (NASDAQ:CCCC) Sees Large Volume IncreaseC4 Therapeutics (NASDAQ:CCCC) Sees Large Volume Increase
americanbankingnews.com - May 13 at 11:54 AM
C4 Therapeutics to Present at Upcoming Investor ConferencesC4 Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - May 12 at 8:02 AM
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest UpdateC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update
americanbankingnews.com - May 3 at 10:26 AM
Did C4 Therapeutics, Inc. (NASDAQ:CCCC) Insiders Buy Up More Shares?Did C4 Therapeutics, Inc. (NASDAQ:CCCC) Insiders Buy Up More Shares?
finance.yahoo.com - May 2 at 9:26 AM
C4 Therapeutics (NASDAQ:CCCC) Sees Unusually-High Trading VolumeC4 Therapeutics (NASDAQ:CCCC) Sees Unusually-High Trading Volume
americanbankingnews.com - April 30 at 11:40 AM
C4 Therapeutics (NASDAQ:CCCC) Shares Gap Up to $30.56C4 Therapeutics (NASDAQ:CCCC) Shares Gap Up to $30.56
americanbankingnews.com - April 27 at 11:18 AM
C4 Therapeutics (NASDAQ:CCCC)  Shares Down 2.3% C4 Therapeutics (NASDAQ:CCCC) Shares Down 2.3%
americanbankingnews.com - April 26 at 12:48 PM
C4 Therapeutics (NASDAQ:CCCC) & Seagen (NASDAQ:SGEN) Head to Head SurveyC4 Therapeutics (NASDAQ:CCCC) & Seagen (NASDAQ:SGEN) Head to Head Survey
americanbankingnews.com - April 26 at 4:26 AM
C4 Therapeutics Inc (CCCC)C4 Therapeutics Inc (CCCC)
investing.com - April 11 at 11:36 PM
C4 Therapeutics Presents Preclinical Data on...C4 Therapeutics Presents Preclinical Data on...
benzinga.com - April 11 at 11:36 PM
C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ...C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ...
apnews.com - April 10 at 6:58 PM
Should You Take Comfort From Insider Transactions At C4 Therapeutics, Inc. (NASDAQ:CCCC)?Should You Take Comfort From Insider Transactions At C4 Therapeutics, Inc. (NASDAQ:CCCC)?
nasdaq.com - April 10 at 1:57 PM
C4 Therapeutics Enters Oversold TerritoryC4 Therapeutics Enters Oversold Territory
nasdaq.com - March 29 at 7:48 PM
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial ResultsC4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
finance.yahoo.com - March 11 at 9:00 PM
C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™
apnews.com - March 10 at 6:05 PM
C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual MeetingC4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 10 at 6:05 PM
How Much Of C4 Therapeutics, Inc. (NASDAQ:CCCC) Do Insiders Own?How Much Of C4 Therapeutics, Inc. (NASDAQ:CCCC) Do Insiders Own?
finance.yahoo.com - March 3 at 8:11 AM
C4 Therapeutics to Participate in Upcoming March Investor ConferencesC4 Therapeutics to Participate in Upcoming March Investor Conferences
finance.yahoo.com - February 24 at 9:43 AM
C4 Therapeutics to Participate in BMO BioPharma Spotlight SeriesC4 Therapeutics to Participate in BMO BioPharma Spotlight Series
finance.yahoo.com - February 11 at 10:05 AM
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an ...C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an ...
apnews.com - January 20 at 1:35 AM
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic MalignanciesC4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
finance.yahoo.com - January 19 at 3:34 PM
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four ...C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four ...
apnews.com - January 7 at 11:26 AM
DateCompanyBrokerageAction
2/5/2021Replimune GroupHC WainwrightBoost Price Target
2/4/2021Replimune GroupSVB LeerinkLower Price Target
11/17/2020Replimune GroupBTIG ResearchInitiated Coverage
11/6/2020Replimune GroupBMO Capital MarketsBoost Price Target
11/2/2020Replimune GroupJefferies Financial GroupInitiated Coverage
10/15/2020Replimune GroupBarclaysBoost Price Target
10/14/2020Replimune GroupRoth CapitalBoost Price Target
10/14/2020Replimune GroupChardan CapitalBoost Price Target
6/3/2020Replimune GroupWedbushReiterated Rating
4/26/2021AlloVirMorgan StanleyBoost Price Target
2/11/2021AlloVirPiper SandlerBoost Price Target
8/24/2020AlloVirJPMorgan Chase & Co.Initiated Coverage
1/7/2019AlloVirBank of AmericaUpgrade
7/10/2018AlloVirThe Goldman Sachs GroupInitiated Coverage
1/20/2021REGENXBIORoyal Bank of CanadaBoost Price Target
1/6/2021REGENXBIORaymond JamesUpgrade
12/15/2020REGENXBIOUBS GroupInitiated Coverage
11/11/2019REGENXBIOEvercore ISIReiterated Rating
11/11/2020AlectorSmith Barney CitigroupLower Price Target
3/5/2020AlectorCitigroupInitiated Coverage
2/18/2020AlectorStifel NicolausInitiated Coverage
12/16/2019AlectorCowenReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.